Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R226-32.

    Genomic strategies for personalized cancer therapy.

    Source

    Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA.

    Abstract

    Numerous recent studies have demonstrated the use of genomic data, particularly gene expression signatures, as clinical prognostic factors in cancer and other complex diseases. These studies highlight the opportunity for strategies to achieve truly personalized cancer treatment. In particular, the ability to develop gene expression signatures will likely allow us to guide the use of currently available cancer drugs, develop new targeted therapeutics, and provide an opportunity to better match the most effective drug or drugs with the molecular characteristics of the individual patient.

    PMID:
    17911165
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Icon for HighWire

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk